Editing Metastatic Hormone-Sensitive Prostate Cancer (section)

== Radiation ==
* '''<span style="color:#ff00ff">STAMPEDE 2018 (Parket et al. Lancet 2018)</span>'''
** Population: 1061 patients with newly diagnosed, with no previous radical treatment, metastatic, hormone-sensitive prostate cancer
** '''Randomized to radiotherapy vs. SOC'''
** Primary outcome: OS
** Secondary outcomes: failure-free survival, progression-free survival, metastatic progression-free survival, prostate cancer-specific survival, and symptomatic local event-free survival.
** '''Two prespecified subgroup analyses tested the effects of prostate radiotherapy by baseline metastatic burden (high vs. low-volume based on CHAARTED definition (see above) and radiotherapy schedule.'''
** '''Results:'''
*** Median follow-up: 37 months
*** '''No benefit in OS (HR 0.92, 95% CI 0.80–1.06)'''
*** '''Significantly improved failure-free survival in radiotherapy group (HR 0.76, 95% CI 0.68–0·84)'''
*** '''Subgroup analysis:'''
**** '''OS significantly improved in low-metastatic burden group (HR 0.68, 95% CI 0.52–0.90) but not high-metastatic burden group (HR 1.07 95% CI 0.90–1.28)'''
**** Failure-free survival significantly improved in both subgroups
** [https://pubmed.ncbi.nlm.nih.gov/30355464/ Parker, Christopher C., et al.] "Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial." ''The Lancet'' 392.10162 (2018): 2353-2366.